Impact of biologics on lung hyperinflation in patients with severe asthma

In asthma, inflammation affects both the proximal and distal airways and can cause significant hyperinflation, which is thought to be a major cause of dyspnea. This is a retrospective observational study evaluating the effect of three months of treatment with different biologic drugs (benralizumab,...

Full description

Saved in:
Bibliographic Details
Published in:Respiratory medicine 2024-04, Vol.225, p.107578-107578, Article 107578
Main Authors: Maniscalco, Mauro, Candia, Claudio, Calabrese, Cecilia, D'Amato, Maria, Matera, Maria Gabriella, Molino, Antonio, Cazzola, Mario
Format: Article
Language:English
Subjects:
Asthma - drug therapy
Biological Products - therapeutic use
Biologics
Forced Expiratory Volume
Humans
Lung
Lung hyperinflation
Omalizumab - therapeutic use
Severe asthma
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In asthma, inflammation affects both the proximal and distal airways and can cause significant hyperinflation, which is thought to be a major cause of dyspnea. This is a retrospective observational study evaluating the effect of three months of treatment with different biologic drugs (benralizumab, dupilumab and omalizumab) on pulmonary hyperinflation in a cohort of patients with severe asthma already receiving regular triple inhaled therapy. Changes in RV, RV/TLC ratio, FRC and FRC/TLC ratio were the primary efficacy measures. Secondary outcomes included FEV1, FVC, FEV1/FVC ratio, IC, IC/TLC ratio, asthma control test, the percentage of eosinophils in the blood and fractional FENO. Benralizumab led to significant changes (p 
ISSN:0954-6111
1532-3064
DOI:10.1016/j.rmed.2024.107578